Outrigger Therapeutics

Outrigger Therapeutics is a Houston-based biotechnology company focused on the discovery and development of next-generation precision oncology treatments. The company was founded by leaders from MD Anderson Cancer Center's Therapeutics Discovery division to target high-value, historically difficult-to-drug oncogenic drivers. Its primary focus is on developing potent and selective small molecule inhibitors of KRAS mutations, including G12D and G12V variants. By leveraging deep expertise in cancer biology and medicinal chemistry, Outrigger aims to provide transformative therapies for patients with genetically defined solid tumors. The company is currently advancing its lead programs through pre-clinical development.